Icon

ZEPOSIA (nda209899)- (EQ 0.23MG BASE,EQ 0.46MG BASE,EQ 0.92MG BASE)

OZANIMOD HYDROCHLORIDE BRISTOL
EQ 0.23MG BASE,EQ 0.46MG BASE,EQ 0.92MG BASE
Yes No
2038-Sep-30 2025-Mar-25
None None
None No
ZEPOSIA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of: • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. • Moderately to severely active ulcerative colitis (UC) in adults.
0 0 0
Total Other Developers 2
Drugs with Suitability No
EQ 0.23MG BASE ** ** - - -
EQ 0.46MG BASE ** ** - - -
EQ 0.92MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.